Breaking Walmart Shares Dip on Cautious Outlook Despite Strong Q2 Sales Coventry City Earns Premier League Promotion After 25-Year Wait Pulitzer Prizes and ALA Launch Traveling Exhibition of Award-Winning Works Democratic Party Narrows 2028 Convention Host City to Three Finalists Melting Glaciers Reveal Remains of Belgian Mountaineers Missing for Over 30 Years

Thursday August 20, 2026

Reporter

IGC Pharma, Inc.

7Articles Published

5Communities Covered

Published Articles

Press Release

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure

Aug 18

Press Release

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

Jul 9

Press Release

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Jul 7

Press Release

IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

Jun 23

Press Release

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Jun 11

Press Release

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

Jun 9

Press Release

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

Jun 2